ClinicalTrials.gg
CompletedNCT00004852Updated Jun 24, 2005

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

A Phase 2 interventional study of Efavirenz and Lamivudine in HIV Infections, sponsored by Glaxo Wellcome. Completed at 66 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies testing efavirenz in HIV Infections — none open to participants now, none under way, none of them phase 3. efavirenz · HIV Infections.

Started
1999
with 9 others
Phase 2
22 of 101
none open now
Registered
19th of 101
by date
Lead sponsor
3 of 101
Glaxo Wellcome

Among the 101 studies testing efavirenz in HIV Infections, this one is one of 10 that started in 1999, is one of 22 in phase 2, and was the 19th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 101 studies testing efavirenz in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About efavirenz

efavirenz: first FDA approval 1998 (SUSTIVA), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies testing efavirenz in HIV Infections as a file.
02

Study summary

The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.

Read the detailed description

Patients are randomized to receive the same total dosage of 3TC either twice a day (Group 1) or once a day (Group 2) in combination with ZDV and EFV over 48 weeks. Viral load measurements will be performed at Weeks 4, 8, 12, 16, 20, 24, and every 8 weeks thereafter.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • Zidovudine
  • Drug Administration Schedule
  • Lamivudine
  • Genotype
  • Phenotype
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Viral Load
  • efavirenz
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are 18 years of age or older.
  • Are -positive.
  • Have a viral load (level of HIV in the blood) of at least 400 copies/ml within 21 days of study entry.
  • Have a greater than 100 cells/mm3 within 21 days of study entry.
  • Agree to practice abstinence or use effective barrier methods of (or, if patient is a woman, unable to have children).

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have taken any antiretroviral (anti-) agent.
  • Are pregnant or breast-feeding.
  • Are unable to absorb food or have trouble taking medicines by mouth.
  • Abuse alcohol or drugs to an extent that may make study participation difficult.
  • Are not likely to be able to complete the 48 weeks of study treatment.
  • Have a history of pancreatitis (inflamed pancreas) or hepatitis within the last 6 months or any evidence of liver disease.
  • Have received an vaccine within the past 3 months or have received gene therapy.
  • Have a severe medical condition such as diabetes or heart trouble.
  • Have been diagnosed with AIDS.
  • Have had radiation therapy or chemotherapy within 30 days of study entry, except for treatment of Kaposi's sarcoma.
  • Are taking medications that affect the immune system within 30 days of study entry.
  • Are taking medications that may interact with the study drugs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

66 sites
  • Phoenix Body Positive
    Phoenix, Arizona 85016, United States
  • Pacific Oaks Research
    Beverly Hills, California 90211, United States
  • AIDS Healthcare Foundation
    Los Angeles, California 900276069, United States
  • Tower ID Med Associates
    Los Angeles, California 90048, United States
  • Davies Med Ctr / c/o HIV Institute
    San Francisco, California 94114, United States
  • Kaiser Foundation Hospital
    San Francisco, California 94118, United States
  • Harbor - UCLA Med Ctr
    Torrance, California 90509, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • IDC Research Initiative
    Altamonte Springs, Florida 32701, United States
  • Bach and Godofsky
    Bradenton, Florida 34205, United States
  • TheraFirst Med Ctrs Inc
    Fort Lauderdale, Florida 33308, United States
  • North Broward Hosp District
    Fort Lauderdale, Florida 33316, United States
  • The Coleman Institute Inc
    Fort Lauderdale, Florida 33334, United States
  • The Coleman Institute Inc
    Fort Pierce, Florida 34950, United States
  • Kaiser Permanente Infectious Diseases
    Atlanta, Georgia 30339, United States
  • AIDS Research Alliance - Chicago
    Chicago, Illinois 60657, United States
  • Infectious Disease of Indiana
    Indianapolis, Indiana 46218, United States
  • Univ of Kentucky Med Ctr
    Lexington, Kentucky 40536, United States
  • Tulane Univ School of Medicine
    New Orleans, Louisiana 70112, United States
  • Boston Med Ctr / Evans - 556
    Boston, Massachusetts 021182393, United States
  • Antibiotic Research Associates
    Kansas City, Missouri 64132, United States
  • East Orange Veterans Administration Med Ctr
    East Orange, New Jersey 07018, United States
  • ID Care Inc
    New Brunswick, New Jersey 08901, United States
  • ID Care Inc
    Princeton, New Jersey 08540, United States
  • ID Care Inc
    Randolph, New Jersey 07869, United States
  • ID Care Inc
    Somerville, New Jersey 08876, United States
  • Albany Med College / Div of HIV Medicine
    Albany, New York 12208, United States
  • North Shore Univ Hosp / Div of Infectious Diseases
    Manhasset, New York 11030, United States
  • St Vincents Hosp / Clinical Research Program
    New York, New York 10011, United States
  • St Lukes / Roosevelt Hosp / HIV Center
    New York, New York 10019, United States
  • Ohio State Univ Hosp Clinic
    Columbus, Ohio 432101228, United States
  • Oklahoma State University / College of Osteopathic Medicine
    Tulsa, Oklahoma 74107, United States
  • Associates in Med and Mental Health
    Tulsa, Oklahoma 74114, United States
  • Miriam Hosp / Brown Univ
    Providence, Rhode Island 02906, United States
  • Methodist Healthcare
    Memphis, Tennessee 38104, United States
  • Univ of Tennessee
    Memphis, Tennessee 38163, United States
  • Vanderbilt Univ Med Ctr
    Nashville, Tennessee 37203, United States
  • Dr David Donnell
    Dallas, Texas 75219, United States
  • Nelson-Tebedo Community Clinic
    Dallas, Texas 75219, United States
  • Univ of Texas Med Branch
    Galveston, Texas 77555, United States
  • Montrose Clinic
    Houston, Texas 77006, United States
  • Baylor College of Medicine / Dept of Medicine
    Houston, Texas 770303498, United States
  • Univ of Texas / Med School at Houston
    Houston, Texas 77030, United States
  • Univ of Texas Health Sciences Ctr
    San Antonio, Texas 782847838, United States
  • Hampton Roads Med Specialists
    Hampton, Virginia 23666, United States
  • Hosp Muniz
    Buenos Aires, Argentina
  • CAICI
    Rosario - Santa Fe, Argentina
  • Universidade de Campinas
    Campinas - SP, Brazil
  • Hosp Evandro Chagas Fioernz
    Manguinhos RJ, Brazil
  • Hosp Univ Clementino Fraga Filho
    Rio de Janeiro - RJ, Brazil
  • Hosp Univ Pedro Ernesto / Univ Estadual do RJ
    Rio de Janeiro - RJ, Brazil
  • Hosp Sao Paulo da Universidade Federal de Sao Paulo
    Sao Paulo - SP, Brazil
  • Southern Alberta HIV Clinic / Foothills Hosp
    Calgary, Alberta, Canada
  • Saint Paul's Hosp
    Vancouver, British Columbia, Canada
  • Sunnybrook Health Science Centre
    Toronto, Ontario, Canada
  • Toronto Gen Hosp
    Toronto, Ontario, Canada
  • Wellesley/Central Site / St Michael's Hospital
    Toronto, Ontario, Canada
  • Clinique Medicale du Quartier Latin
    Montreal, Quebec, Canada
  • Clinique Medicale L'Actuele
    Montreal, Quebec, Canada
  • Centre Hospitalier Universitaire de Quebec
    Ste Foy, Quebec, Canada
  • Caguas Regional Hosp
    Caguas, 00726, Puerto Rico
  • Hosp San Cristobal-Edif A
    Cotto Laurel, 00780, Puerto Rico
  • Carlos Leon-Valiente MD
    Guaynabo, 00966, Puerto Rico
  • Ramon Ramirez Ronda MD
    Mayaguez, 00680, Puerto Rico
  • San Juan AIDS Program
    Santurce, 00908, Puerto Rico
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00004852
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Start date
Sep 1999
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2000. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efavirenz · Lamivudine · Zidovudine

Start the discussion